BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/4/2018 1:15:45 PM | Browse: 1432 | Download: 2777
 |
Received |
|
2018-02-05 06:01 |
|
Peer-Review Started |
|
2018-02-05 06:28 |
|
First Decision by Editorial Office Director |
|
2018-02-23 19:52 |
|
Return for Revision |
|
2018-02-26 03:37 |
|
Revised |
|
2018-02-26 07:33 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2018-03-06 09:43 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2018-03-06 16:59 |
|
Articles in Press |
|
2018-03-06 16:59 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-04-03 05:48 |
|
Publish the Manuscript Online |
|
2018-04-04 13:15 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Prospective Study |
| Article Title |
Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Masayoshi Yada, Masayuki Miyazaki, Kosuke Tanaka, Akihide Masumoto and Kenta Motomura |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Masayoshi Yada, MD, PhD, Doctor, Doctor, Department of Hepatology, Iizuka Hospital, 3-83 Yoshio-machi, Iizuka 820－8505, Fukuoka, Japan. myadah1@aih-net.com |
| Key Words |
Sofosbuvir; Ribavirin; Genotype 2; Hepatitis C virus; Interferon-based therapy; Hepatocellular carcinoma |
| Core Tip |
The real-world efficacy of sofosbuvir/ribavirin therapy for genotype 2 hepatitis C virus infection in Japan is high. Sofosbuvir/ribavirin therapy is safe and highly tolerated. History of hepatocellular carcinoma or interferon-based therapy independently reduces the efficacy of sofosbuvir/ribavirin therapy. Progressive liver fibrosis may attenuate the antiviral effect of sofosbuvir/ribavirin therapy. |
| Publish Date |
2018-04-04 13:15 |
| Citation |
Yada M, Miyazaki M, Tanaka K, Masumoto A, Motomura K. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus. World J Gastroenterol 2018; 24(13): 1478-1485 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i13/1478.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i13.1478 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
